





an Open Access Journal by MDPI

Psoriasis: Pathology, Clinical Presentation, and Treatment

Guest Editor:

Dr. Raffaella Cascella

1. Department of Biomedicine and Prevention, School of Medicine, University of Rome "Tor Vergata", Rome, Italy 2. Department of Biomedical Sciences, Catholic University Our Lady of Good Counsel, 1000 Tirana, Albania

Deadline for manuscript submissions:

closed (10 October 2022)

Message from the Guest Editor

Psoriasis is a chronic immune-mediated inflammatory skin disease with a prevalence of 2–3% worldwide. Psoriasis is described multifactorial disorder as in which environmental and genetic/epigenetic factors are likely to influence the susceptibility to the disease. Despite the identification of different etiopathogenetic mechanisms involved in the onset and progression of the disease, many pieces are still missing to obtain a complete knowledge of this disease. On this subject, the identification of new biomarkers (preclinical, clinical, genomic, epigenomic, pharmacogenomic) and the possibility of applying precision medicine protocols to psoriasis could improve patients' healthcare by providing the optimal therapeutic strategy and reducing the disease progression. In fact, precision medicine protocols will aim to optimize diagnostic procedures, treatment options, and the development of new therapeutic strategies. This Special Issue aims to highlight the role of personalized medicine in clinical practice, providing a complete overview of the disease and highlighting its critical issues in its management.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us